Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial The crisis of purchasing imported consumables in bulk in 10 provinc ...

Johnson & Johnson terminates global Phase III clinical trial of Stelara for the treatment of systemic lupus erythematosus Trikafta, a triple combination therapy for CF in patients with specific gene ...

INR:9523. newcastle horse racing tips today Is the Cold Winter of Private Medical Care Coming? In-depth Analysis of ...

What does the Red Queen represent in Alice in Wonderland. INR:7123. What does the Red Queen represent in Alice in Wonderland Fingolimod blocks HIV infection and transmission in hu ...

Aero flavours list️ In 2019, more than 10,000 cases were investigated and dealt with. Past stories of drug counterfeiting that were not shown on ...

Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. Its first approved indication could come as early ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...